Odactra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of allergic rhinitis, growing awareness of immunotherapy benefits, expansion of allergy specialist practices, availability of sublingual immunotherapy products, improved diagnosis of dust mite allergies.

The growth in the forecast period can be attributed to growing adoption of preventive allergy care, expansion of pediatric and adolescent allergy treatment, rising demand for convenient home-administered therapies, increasing focus on immune tolerance development, continued innovation in allergen-based biologics. Major trends in the forecast period include increasing adoption of allergen immunotherapy tablets, rising focus on long-term disease-modifying allergy treatments, expansion of home-based allergy management, growing demand for non-injection immunotherapy options, enhanced patient adherence programs.

The increasing prevalence of allergic diseases is expected to propel the growth of the Odactra market going forward. Allergic diseases are conditions that arise from an abnormal immune response to substances that are typically harmless. The growth in allergic diseases is driven by factors such as environmental changes, higher exposure to allergens, urbanization, and shifts in lifestyle and dietary patterns. Odactra works through allergen-specific immunotherapy by gradually exposing individuals to dust mite allergens, helping to desensitize the immune system. This approach reduces allergic reactions, eases symptoms, and provides long-term relief for individuals with dust mite allergies. For instance, in April 2024, according to Allergy UK, a UK-based charity supporting people affected by allergies, more than five million individuals require specialist care for severe allergies, and by 2026, at least one in two people in Europe is expected to be affected by allergies. Therefore, the growing prevalence of allergic diseases is driving the growth of the Odactra market.

The increase in the number of hospitals is expected to fuel the growth of the Odactra market going forward. A hospital is a healthcare facility that delivers medical care to patients with illnesses or injuries, including emergency services, surgical procedures, and specialized treatments. The growth in the number of hospitals is driven by rising healthcare needs, population growth, technological advancements in medicine, and increased investment in healthcare infrastructure. Greater availability of healthcare facilities improves access to allergy diagnosis and treatment services. The expansion of hospitals offering specialized care, including immunotherapy for dust mite-induced allergic rhinitis, is expected to increase demand for treatments such as Odactra. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals in 2023, reflecting a 0.591% increase from 6,093 hospitals in 2022. Therefore, the growing number of hospitals is driving the growth of the Odactra market.

Major companies operating in the Odactra market are focusing on developing innovative solutions, such as advanced sublingual allergy immunotherapy tablets, to address the rising demand for improved patient adherence, non-invasive treatment methods, and long-term management of allergy-related conditions. Sublingual allergy immunotherapy tablets deliver controlled doses of allergens orally to gradually desensitize the immune system, offering a more convenient and patient-friendly alternative to traditional injectable therapies that require frequent clinical visits. For instance, in January 2023, ALK-Abelló, a Denmark-based research-driven pharmaceutical company, announced that the US Food and Drug Administration approved ODACTRA tablets for sublingual use in adolescents aged 12 to 17 years. This expanded approval enables the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, in individuals aged 12 to 65 years. ODACTRA functions as an immunotherapy for confirmed house dust mite allergies but is not intended to provide immediate symptom relief.

Major companies operating in the odactra market are ALK Abello A/s.

North America was the largest region in the odactra market in 2025. The regions covered in the odactra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the odactra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the Odactra market by increasing costs of imported allergen extracts, pharmaceutical-grade excipients, blister packaging materials, and quality testing equipment. Retail and hospital pharmacies in North America and Europe are most affected due to reliance on imported immunotherapy inputs, while Asia-Pacific faces cost pressures in scaling allergen manufacturing. These tariffs are contributing to higher therapy pricing and distribution costs. However, they are also encouraging localized allergen production, regional manufacturing investments, and strengthened domestic immunotherapy supply chains.

The odactra market research report is one of a series of new reports that provides odactra market statistics, including odactra industry global market size, regional shares, competitors with a odactra market share, detailed odactra market segments, market trends and opportunities, and any further data you may need to thrive in the odactra industry. This odactra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Odactra is an allergy immunotherapy therapy used for the treatment of allergic rhinitis caused by dust mites. It works by gradually reducing the immune system’s sensitivity to dust mite allergens, helping to alleviate symptoms such as sneezing, nasal discharge, and itchy or watery eyes. Odactra is intended to deliver long-term symptom relief by altering the body’s immune response to allergens over time.

The main types of indications for Odactra include house dust mite-induced allergic rhinitis and allergic conjunctivitis. House dust mite-induced allergic rhinitis is an allergic condition marked by nasal inflammation, sneezing, itching, and congestion resulting from exposure to dust mites. It is used across different age groups, including adults (18-65 years), adolescents (12-17 years), and children (5-11 years), and is distributed through multiple channels such as retail pharmacies, online pharmacies, and hospital pharmacies.

The odactra market consists of sales of tablets, allergy testing kits, sublingual immunotherapy (SLIT) delivery systems, and patient adherence tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.